KPV

KPV was isolated in the 1980s as the active anti-inflammatory tripeptide C-terminus of alpha-melanocyte stimulating hormone (alpha-MSH). It was discovered during efforts to separate anti-inflammatory effects from skin pigmentation. What it is: KPV is a naturally derived tripeptide (Lys-Pro-Val) that acts as a potent immunomodulatory and anti-inflammatory agent. It is categorized under Tissue Repair/Immune. Proposed Mechanisms & Research Findings: It works by inhibiting the NF-kB signaling pathway, thereby reducing the production of pro-inflammatory cytokines (like TNF-alpha, IL-1beta, and IL-6). It also exhibits antimicrobial properties. Regulatory & Safety Status: It is not FDA approved. It is widely used in research settings and experimental compounding. Online gray-market sourcing lacks clinical validation and sterile verification. Athletic & Anti-Doping Status: KPV is not prohibited by WADA or USADA, as it does not bind to melanocortin-1 receptors or stimulate performance-enhancing hormones.